Theravance Biopharma, Inc.

Historical 13F Holders

Symbol
TBPH
CUSIP
G8807B106
All holders as of
Q2 2026
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for G8807B106 since 12/18/2024, newest first.

Filer % of Class Filed
Weiss Asset Management LP 13D/A Amendment 4
0% 9/25/2026
Event 9/23/2026
Newtyn Management, LLC 13G/A Amendment 3
6.7%
Checked 5% or less
8/14/2026
Event 6/30/2026
Madison Avenue Partners, LP 13G/A Amendment 5
17.7% 8/14/2026
Event 6/30/2026
Weiss Asset Management LP 13D/A Amendment 3
14.5% 3/25/2026
Event 3/23/2026
Newtyn Management, LLC 13G/A Amendment 2
8.5% 2/17/2026
Event 12/31/2025
BlackRock, Inc. 13G/A Amendment 13 6.5% 4/30/2025
Event 3/31/2025
Newtyn Management, LLC 13G/A Amendment 1
9.7% 2/14/2025
Event 12/31/2024

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q2 185 48.8 M $857 M
2026 Q1 181 50.2 M $814 M
2025 Q4 177 49.7 M $930 M
2025 Q3 171 48.7 M $711 M
2025 Q2 140 48.0 M $529 M
2025 Q1 137 44.9 M $401 M
2024 Q4 131 44.9 M $422 M
2024 Q3 124 46.0 M $371 M
2024 Q2 137 47.8 M $406 M
2024 Q1 129 48.9 M $438 M
2023 Q4 127 49.4 M $555 M
2023 Q3 121 50.8 M $439 M
2023 Q2 128 52.8 M $546 M
2023 Q1 123 60.2 M $653 M
2022 Q4 133 63.6 M $713 M
2022 Q3 140 64.3 M $652 M
2022 Q2 120 64.4 M $584 M
2022 Q1 137 63.3 M $605 M
2021 Q4 129 59.7 M $660 M
2021 Q3 134 60.7 M $449 M
2021 Q2 114 60.8 M $883 M
2021 Q1 120 53.6 M $1.09 B
2020 Q4 113 53.5 M $952 M
2020 Q3 126 52.5 M $776 M
2020 Q2 131 53.0 M $1.11 B
2020 Q1 114 56.9 M $1.32 B
2019 Q4 114 45.4 M $1.18 B
2019 Q3 95 46.2 M $900 M
2019 Q2 116 48.9 M $799 M
2019 Q1 112 48.5 M $1.10 B
2018 Q4 99 48.2 M $1.23 B
2018 Q3 102 48.7 M $1.59 B
2018 Q2 92 47.9 M $1.09 B
2018 Q1 95 47.8 M $1.16 B
2017 Q4 86 46.9 M $1.31 B
2017 Q3 90 47.3 M $1.62 B
2017 Q2 96 46.3 M $1.84 B
2017 Q1 98 45.2 M $1.66 B
2016 Q4 102 43.9 M $1.40 B
2016 Q3 101 35.3 M $1.28 B
2016 Q2 98 33.9 M $770 M
2016 Q1 83 28.2 M $529 M
2015 Q4 88 27.7 M $453 M
2015 Q3 84 20.5 M $226 M
2015 Q2 91 22.4 M $292 M
2015 Q1 89 20.9 M $362 M
2014 Q4 96 20.8 M $310 M
2014 Q3 97 21.7 M $501 M
2014 Q2 98 20.7 M $659 M
2014 Q1 1 842 $14.6 k